EP0773719A4 - COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGENIC RECEPTORS - Google Patents

COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGENIC RECEPTORS

Info

Publication number
EP0773719A4
EP0773719A4 EP95926328A EP95926328A EP0773719A4 EP 0773719 A4 EP0773719 A4 EP 0773719A4 EP 95926328 A EP95926328 A EP 95926328A EP 95926328 A EP95926328 A EP 95926328A EP 0773719 A4 EP0773719 A4 EP 0773719A4
Authority
EP
European Patent Office
Prior art keywords
compositions
cells containing
androgen receptors
containing androgen
targeting materials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95926328A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0773719A1 (en
Inventor
John A Petros
Dennis C Liotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of EP0773719A1 publication Critical patent/EP0773719A1/en
Publication of EP0773719A4 publication Critical patent/EP0773719A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
EP95926328A 1994-07-29 1995-07-24 COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGENIC RECEPTORS Ceased EP0773719A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/283,238 US6468981B1 (en) 1994-07-29 1994-07-29 Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US283238 1994-07-29
PCT/US1995/009293 WO1996003875A1 (en) 1994-07-29 1995-07-24 Compositions for targeting materials to cells containing androgen receptors

Publications (2)

Publication Number Publication Date
EP0773719A1 EP0773719A1 (en) 1997-05-21
EP0773719A4 true EP0773719A4 (en) 1998-09-02

Family

ID=23085145

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95926328A Ceased EP0773719A4 (en) 1994-07-29 1995-07-24 COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGENIC RECEPTORS

Country Status (5)

Country Link
US (1) US6468981B1 (it)
EP (1) EP0773719A4 (it)
AU (1) AU3071995A (it)
CA (1) CA2197770A1 (it)
WO (1) WO1996003875A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027008A2 (de) * 1995-02-28 1996-09-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin Mittel zur therapie von tumoren und anderen hyperplasien
CA2239976A1 (en) * 1995-09-20 1997-03-27 Paul A. Zamecnik Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
EP0856052A1 (en) * 1995-09-20 1998-08-05 University of Massachusetts Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
WO2000011019A1 (en) * 1998-08-21 2000-03-02 Felix Frey Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
DE60236520D1 (de) * 2001-08-16 2010-07-08 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
EP1844793A1 (en) * 2006-04-13 2007-10-17 D'Angelo, Sante Cyclic AMP binding molecule as vehicle for gene therapy

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003162A1 (en) * 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
WO1992014493A1 (en) * 1991-02-20 1992-09-03 Christopher Capelli Non-protein intracellular receptor binding conjugates and a method of use thereof
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
WO1992022635A1 (en) * 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
WO1993005162A1 (en) * 1991-08-28 1993-03-18 The University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993007883A1 (en) * 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994004696A1 (en) * 1992-08-25 1994-03-03 Miles Inc. Translocation signal facilitated nuclear delivery of macromolecules
DE4308095A1 (de) * 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Arzneimittelwirkstoffen mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
ES2078521T3 (es) 1990-05-18 1995-12-16 Boehringer Ingelheim Int Nuevos conjugados de proteina-polication.
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003162A1 (en) * 1989-08-31 1991-03-21 City Of Hope Chimeric dna-rna catalytic sequences
WO1992014493A1 (en) * 1991-02-20 1992-09-03 Christopher Capelli Non-protein intracellular receptor binding conjugates and a method of use thereof
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
WO1992022635A1 (en) * 1991-06-05 1992-12-23 University Of Connecticut Targeted delivery of genes encoding secretory proteins
WO1993005162A1 (en) * 1991-08-28 1993-03-18 The University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993007883A1 (en) * 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994004696A1 (en) * 1992-08-25 1994-03-03 Miles Inc. Translocation signal facilitated nuclear delivery of macromolecules
DE4308095A1 (de) * 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Arzneimittelwirkstoffen mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
WO1994023751A1 (de) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. WU ET AL: "Tageting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 264, no. 29, 15 October 1989 (1989-10-15), MD US, pages 16985 - 16987, XP002065973 *
G. WU ET AL: "Receptor Mediated Gene Delivery In Vivo", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 266, no. 22, 5 August 1991 (1991-08-05), MD US, pages 14338 - 14342, XP002065972 *
J. WILSON ET AL: "Hepatocyte-directed Gene Transfer in Vivo Leads to Transient Improvement of Hypercholesterolemia in Low Density Lipoprotein Receptor-deficient Rabbits", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 267, no. 2, 15 January 1992 (1992-01-15), MD US, pages 963 - 967, XP002065974 *
M. BHATTACHARJEE ET AL: "Protein Purification Using a Soluble Affinity Matrix: Purification of Estrogen Receptor with Estradiol-Polylysine Conjugate", ANALYTICAL BIOCHEMISTRY., vol. 201, no. 2, March 1992 (1992-03-01), NEW YORK US, pages 233 - 236, XP002065971 *
See also references of WO9603875A1 *

Also Published As

Publication number Publication date
US6468981B1 (en) 2002-10-22
AU3071995A (en) 1996-03-04
CA2197770A1 (en) 1996-02-15
EP0773719A1 (en) 1997-05-21
WO1996003875A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
US5800816C1 (en) Cosmetic compositions
HUP0101419A3 (en) Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
ZA9510138B (en) Cosmetic compositions containing betullnic acid
PL339919A1 (en) Stable cosmetic compositions
HUP0002052A3 (en) Filled polyethylene compositions
ZA95922B (en) Cosmetic compositions
GB9703531D0 (en) Improvements relating to chemical compositions
ZA986423B (en) Sedimentation stabilized radiation-curable filled compositions
GR3030131T3 (en) Oral liquid compositions containing paroxetine resinate
GB9704989D0 (en) Improvements relating to hard-surface cleaning compositions
PL338186A1 (en) Beneficial agent compositions containing alpha-hydroxyesters
HUP0102857A3 (en) Fuel compositions containing propoxilate
HK1021700A1 (en) Novel powder compositions
EP0773719A4 (en) COMPOSITIONS FOR TARGETING MATERIALS TO CELLS CONTAINING ANDROGENIC RECEPTORS
GB2311009B (en) Pharmaceutical compositions containing tagetes plants
HUP9900978A3 (en) Composition containing diosgenin
IL134651A0 (en) Pharmaceutical compositions containing an anti-androgen
GB9408259D0 (en) Cosmetic compositions
PL336705A1 (en) Cosmetic compositions containing valkirian earth gels
GB9405322D0 (en) Powder cosmetic compositions
GB9405320D0 (en) Powder cosmetic compositions
PL337782A1 (en) Powdered compositions of single-film liposomes
EP0930361A4 (en) CELLULAR COMPOSITIONS
GB9415323D0 (en) Cosmetic compositions
EP1105518A4 (en) USE OF mCRP TO INTRODUCE MATERIALS IN CELLS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980714

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000705

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020927